Qualitas Health Ltd.

West Jerusalem, Israel

Qualitas Health Ltd.

West Jerusalem, Israel
SEARCH FILTERS
Time filter
Source Type

All of Qualitas Health's products feature 100% vegan, algae-based ingredients that are specifically designed to deliver highly bioavailable omega-3s in an easy to digest form. Their flagship ingredient Almega PL® delivers the omega-3 EPA naturally bound to polar lipids to provide superior digestibility and absorption. EPA is best known for its cardiovascular benefits, though it also has a positive impact on mood, skin and joint health. "Omega-3 is an essential nutrient that represents an exciting market, currently dominated by fish and krill. Many people don't realize, however, that fish and krill get their omega-3s from algae," said Qualitas Health CEO Miguel Calatayud. "We are thrilled to be partnering with the expert farmers at Green Stream Farms to bring vegan, sustainably produced nutritional products to more people than ever before, and to become the truly green alternative in the omega-3 world." Added Tom Richard, CEO of Green Stream Farms: "We are proud to partner with Qualitas Health to produce algae on a commercial scale. Our partnership will lead the industry in taking a true farming approach to algae production. We plan to continue to find innovative ways for algae to become a more sustainable product." Algae is a super crop packed with nutrients like protein, omega-3s and omega-7s, capable of flourishing in arid environments and utilizing readily available inputs like salt water and CO2 to grow. Compared to other staple crops, algae is both faster growing and more nutrient dense: algae produces 300 times more protein per acre than peas. Qualitas Health's new algae farm in Columbus, New Mexico, will expand the company's total acreage to 150 acres in cultivation, roughly equivalent to 45,000 acres of peas in terms of protein yield. Until recently, the nutritional promise of algae remained unrealized, as it proved too expensive to farm in substantial quantities. Qualitas has created a global algae-based products platform to deliver vegan, highly bioavailable nutritional products with full traceability, starting with omega-3 supplements. The Green Stream Farms partnership will enable Qualitas Health to expand its algae production to meet growing national and international demand for its vegan omega-3 supplements. About Qualitas Health: Qualitas Health is a food and nutrition company that is on a mission to revolutionize the way we nourish humanity by unleashing the potential of algae. An industry leader in algae cultivation, Qualitas Health has developed a proprietary platform to launch fully sustainable, vegan, algae-based nutritional products at scale. For more information, visit http://www.qualitas-health.com/. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/qualitas-health-announces-new-production-partnership-to-triple-algae-production-becoming-global-alternative-in-the-omega-3-market-300463856.html


Patent
Qualitas Health Ltd. | Date: 2013-12-18

Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.


Kagan M.L.,Qualitas Health Ltd | Sullivan D.W.,Gad Consulting Services | Gad S.C.,Gad Consulting Services | Ballou C.M.,Gad Consulting Services
International Journal of Toxicology | Year: 2014

Almega PL is an eicosapentaenoic acid-rich ω-3 oil that is isolated from Nannochloropsis oculata algae and developed as a dietary supplement. The safety of the algal oil was evaluated in 14- and 90-day studies in Sprague-Dawley rats by oral gavage at dose levels of 0, 250, 500, and 2500 mg/kg/d and 0, 200, 400, and 2000 mg/kg/d, respectively. No mortalities occurred and no signs of toxicity were observed during the studies. No treatment-related effects were seen for body weight, food consumption, ophthalmology, neurological effects, urinalysis, clinical pathology, gross pathology, organ weights, or histopathology. Although statistically significant effects were noted for some end points, none were considered to be of toxicological significance. The no observed adverse effect level for Almega PL was 2000 mg/kg/d. Additionally, Almega PL was not mutagenic in Salmonella typhimurium or Escherichia coli, did not induce chromosome aberrations in Chinese hamster ovary cells, and did not induce genotoxic effects in vivo in rat bone marrow erythrocytes. © 2014, SAGE Publications. All rights reserved.


Kagan M.L.,Qualitas Health Ltd | Sullivan D.W.,Jr | Gad S.C.,Gad Consulting Services | Ballou C.M.,Gad Consulting Services
International journal of toxicology | Year: 2014

Almega PL is an eicosapentaenoic acid-rich ω-3 oil that is isolated from Nannochloropsis oculata algae and developed as a dietary supplement. The safety of the algal oil was evaluated in 14- and 90-day studies in Sprague-Dawley rats by oral gavage at dose levels of 0, 250, 500, and 2500 mg/kg/d and 0, 200, 400, and 2000 mg/kg/d, respectively. No mortalities occurred and no signs of toxicity were observed during the studies. No treatment-related effects were seen for body weight, food consumption, ophthalmology, neurological effects, urinalysis, clinical pathology, gross pathology, organ weights, or histopathology. Although statistically significant effects were noted for some end points, none were considered to be of toxicological significance. The no observed adverse effect level for Almega PL was 2000 mg/kg/d. Additionally, Almega PL was not mutagenic in Salmonella typhimurium or Escherichia coli, did not induce chromosome aberrations in Chinese hamster ovary cells, and did not induce genotoxic effects in vivo in rat bone marrow erythrocytes. © The Author(s) 2014.


Kagan M.L.,Qualitas Health Ltd. | Matulka R.A.,Burdock Group
Toxicology Reports | Year: 2015

Nannochloropsis oculata is a marine-water microalgae that is considered to be a good source of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA), utilized in the production of an omega-3 oil for use as a dietary supplement. This study investigates the safety of N. oculata in male and female Sprague-Dawley rats administered a 0 or 10. mL/kg bw/rat N. oculata (10E8 viable cells/mL) suspension by oral gavage once daily for 14 consecutive days. No mortalities occurred and no signs of toxicity were observed during the study. No treatment-related effects were seen for body weight, food consumption, urinalysis, clinical chemistry, hematology, gross pathology, organ weights, or histopathology. Although statistically significant effects were noted for some endpoints, none were considered to be of toxicological significance. The N. oculata suspension was concluded to have no toxicity in rats, confirming that the algal strain used in the production of omega-3 oil is not pathogenic when administered orally to rats. © 2015 The Authors.


Kagan M.L.,Qualitas Health Ltd. | Levy A.,Pharmaseed Ltd. | Leikin-Frenkel A.,Tel Aviv University
Food and Function | Year: 2015

Long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) exert health benefits which are dependent upon their incorporation into blood, cells and tissues. Plasma and tissue deposition of LC n-3 PUFA from oils extracted from the micro-algae Nannochloropsis oculata and from krill were compared in rats. The algal oil provides eicosapentaenoic acid (EPA) partly conjugated (15%) to phospholipids and glycolipids but no docosahexaenoic acid (DHA), whereas krill oil provides both EPA and DHA conjugated in part (40%) to phospholipids. Rats fed a standard diet received either krill oil or polar-lipid rich algal oil by gavage daily for 7 days (5 ml oil per kg body weight each day). Fatty acid concentrations were analyzed in plasma, brain and liver, and two adipose depots since these represent transport, functional and storage pools of fatty acids, respectively. When measuring total LC n-3 PUFA (sum of EPA, docosapentaenoic acid (DPA) and DHA), there was no statistically significant difference between the algal oil and krill oil for plasma, brain, liver and gonadal adipose tissue. Concentrations of LC n-3 PUFA were higher in the retroperitoneal adipose tissue from the algal oil group. Tissue uptake of LC n-3 PUFA from an algal oil containing 15% polar lipids (glycolipids and phospholipids) was found to be equivalent to krill oil containing 40% phospholipids. This may be due to glycolipids forming smaller micelles during ingestive hydrolysis than phospholipids. Ingestion of fatty acids with glycolipids may improve bioavailability, but this needs to be further explored. © The Royal Society of Chemistry 2015.


Kagan M.L.,Qualitas Health Ltd. | West A.L.,University of Southampton | Zante C.,MPS Hamburg GmbH | Calder P.C.,University of Southampton
Lipids in Health and Disease | Year: 2013

Background: The long-chain n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have human health benefits. Alternatives to fish as sources of EPA and DHA are needed. Oil from the micro-algae Nannochloropsis oculata contains a significant amount of EPA conjugated to phospholipids and glycolipids and no DHA. Krill oil contains EPA and DHA conjugated to phospholipids. We compare the appearance of fatty acids in blood plasma of healthy humans after consuming a high fat meal followed by either algal oil or krill oil. Methods. Ten healthy males aged 18-45 years consumed a standard high fat (55 g) breakfast followed by either algal oil (providing 1.5 g EPA and no DHA) or krill oil (providing 1.02 g EPA and 0.54 g DHA). All participants consumed both oils in random order and separated by 7 days. Blood samples were collected before the breakfast and at several time points up to 10 hours after taking the oils. Fatty acid concentrations (μg/ml) in plasma were determined by gas chromatography. Results: Fatty acids derived mainly from the breakfast appeared rapidly in plasma, peaking about 3 hours after consuming the breakfast, and in a pattern that reflected their content in the breakfast. There were time-dependent increases in the concentrations of both EPA and DHA with both algal oil (P < 0.001 for EPA; P = 0.027 for DHA) and krill oil (P < 0.001 for both EPA and DHA). The concentration of EPA was higher with algal oil than with krill oil at several time points. DHA concentration did not differ between oils at any time point. The maximum concentration of EPA was higher with algal oil (P = 0.010) and both the area under the concentration curve (AUC) and the incremental AUC for EPA were greater with algal oil (P = 0.020 and 0.006). There was no difference between oils in the AUC or the incremental AUC for DHA. Conclusion: This study in healthy young men given a single dose of oil indicates that the polar-lipid rich oil from the algae Nannochloropis oculata is a good source of EPA in humans. © 2013 Kagan et al.; licensee BioMed Central Ltd.


Long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) exert health benefits which are dependent upon their incorporation into blood, cells and tissues. Plasma and tissue deposition of LC n-3 PUFA from oils extracted from the micro-algae Nannochloropsis oculata and from krill were compared in rats. The algal oil provides eicosapentaenoic acid (EPA) partly conjugated (15%) to phospholipids and glycolipids but no docosahexaenoic acid (DHA), whereas krill oil provides both EPA and DHA conjugated in part (40%) to phospholipids. Rats fed a standard diet received either krill oil or polar-lipid rich algal oil by gavage daily for 7 days (5 ml oil per kg body weight each day). Fatty acid concentrations were analyzed in plasma, brain and liver, and two adipose depots since these represent transport, functional and storage pools of fatty acids, respectively. When measuring total LC n-3 PUFA (sum of EPA, docosapentaenoic acid (DPA) and DHA), there was no statistically significant difference between the algal oil and krill oil for plasma, brain, liver and gonadal adipose tissue. Concentrations of LC n-3 PUFA were higher in the retroperitoneal adipose tissue from the algal oil group. Tissue uptake of LC n-3 PUFA from an algal oil containing 15% polar lipids (glycolipids and phospholipids) was found to be equivalent to krill oil containing 40% phospholipids. This may be due to glycolipids forming smaller micelles during ingestive hydrolysis than phospholipids. Ingestion of fatty acids with glycolipids may improve bioavailability, but this needs to be further explored.


Trademark
Qualitas Health Inc. | Date: 2015-08-04

Algae extracts for use in the manufacture of dietary supplements, food and pharmaceuticals. Dietary and nutritional supplements containing algae. Processed algae for human consumption.


Trademark
Qualitas Health Inc. | Date: 2016-11-23

Dietary and nutritional supplements containing algae. Processed algae for human consumption.

Loading Qualitas Health Ltd. collaborators
Loading Qualitas Health Ltd. collaborators